Lupin Ltd
LUPINBSE 500257PharmaceuticalsMkt cap ₹92,784 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹8,277 Cr
YoY +32.0%QoQ +10.7%
Net profit · Q1 FY27
₹1,417 Cr
YoY +16.0%QoQ -3.5%
Net margin · Q1 FY27
17.1%
-2.4 pts vs Q1 FY26
Net profit · FY26
₹5,355 Cr
YoY +62.0%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 8,277 | 7,475 | 7,168 | 7,048 | 6,268 | +32.0% |
| Other income | 130 | 141 | 115 | 90.00 | 79.04 | +64.9% |
| Total income | 8,407 | 7,615 | 7,282 | 7,138 | 6,347 | +32.5% |
| Profit before tax | 2,017 | 1,928 | 1,522 | 2,007 | 1,416 | +42.5% |
| Tax | 600 | 459 | 342 | 522 | 194 | +209.3% |
| Net profit | 1,417 | 1,469 | 1,181 | 1,485 | 1,221 | +16.0% |
| Net margin | 17.1% | 19.6% | 16.5% | 21.1% | 19.5% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 27,958 | 22,708 | 20,011 | 16,642 | 16,405 | +23.1% |
| Other income | 424 | 196 | 120 | 73.36 | 142 | +116.8% |
| Total income | 28,382 | 22,904 | 20,131 | 16,715 | 16,547 | +23.9% |
| Profit before tax | 6,873 | 4,015 | 2,422 | 716 | -1,373 | +71.2% |
| Tax | 1,517 | 709 | 487 | 269 | 137 | +114.1% |
| Net profit | 5,355 | 3,306 | 1,936 | 448 | -1,509 | +62.0% |
| Net margin | 19.2% | 14.6% | 9.7% | 2.7% | -9.2% |
BIC's take
We haven't covered Lupin Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:49 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.